Stendra approval in hand, Vivus looks like a target

Vivus ($VVUS) finally won an approval from FDA: The agency has blessed its erectile dysfunction treatment, Stendra. Now, Vivus has to figure out how to sell it--or find a buyer for the whole company. Report